Drug Trial Radar · NCT07588646
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Jun 29, 2021
Primary completion
Nov 30, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects. A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and nintedanib in healthy male subjects.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HEC585Drug
DDI of HEC585 and Pirfenidone:HEC585, once daily,D5-D14 and D18-D27; DDI of HEC585 and Nintedanib:HEC585,once daily,D14-D23 and D27-D36
NintedanibDrug
DDI of HEC585 andNintedanib:Nintedanib,twice a day,D1-D7 and D30-D36
PirfenidoneDrug
DDI of HEC583 and Pirfenidone: Pirfenidone:three times a day,D1-D3 and D25-D27
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve from 0 to 24 hours [AUC (0~24)]Time frame: Day 3 for Pirfenidone monotherapy phase; Day 14 for HEC585 monotherapy phase; Day 27 for Combination phase.
- Maximum Plasma Concentration (Cmax)Time frame: Day 3 for Pirfenidone monotherapy phase; Day 14 for HEC585 monotherapy phase; Day 27 for Combination phase.
- Area under the curve from 0 to 24 hours [AUC (0~24)]Time frame: Day 7 for Nintedanib monotherapy phase; Day 23 for HEC585 monotherapy phase; Day 36 for Combination phase.
- Observed Plasma Concentration (Cmax)Time frame: Day 7 for Nintedanib monotherapy phase; Day 23 for HEC585 monotherapy phase; Day 36 for Combination phase.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.